Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | FNTA | P49354 | 3/20 | 0.56 |
| ▸ | FNTB | P49356 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.56 |
| ▸ | SQLE | Q14534 | 4/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL794656 | 1.00 | KMT2A (0.62) | KMT2AMEN1CYP3A4ALOX15FNTA | |
| SCHEMBL20879345 | 1.00 | KMT2A (0.62) | KMT2AMEN1CYP3A4ALOX15FNTA | |
| SCHEMBL8461809 | 0.98 | KMT2A (0.67) | KMT2AMEN1CYP3A4ALOX15FNTA | |
| SCHEMBL3951138 | 0.98 | KMT2A (0.67) | KMT2AMEN1CYP3A4ALOX15FNTA | |
| SCHEMBL2495182 | 0.84 | KMT2A (0.65) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL31406757 | 0.82 | KMT2A (0.70) | KMT2AMEN1CYP3A4ALOX15FNTA | |
| SCHEMBL11305628 | 0.82 | KMT2A (0.62) | KMT2AMEN1CYP3A4ALOX15FNTA | |
| SCHEMBL31406758 | 0.82 | KMT2A (0.70) | KMT2AMEN1CYP3A4ALOX15FNTA | |
| SCHEMBL11305625 | 0.82 | KMT2A (0.62) | KMT2AMEN1CYP3A4ALOX15FNTA | |
| SCHEMBL31406762 | 0.82 | KMT2A (0.70) | KMT2AMEN1CYP3A4ALOX15FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267571-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2013-10-10 | — | — | US | claimed |
| EP-2616056-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | Neuroquest Inc. (CA) | 2013-07-24 | — | — | EP | claimed |
| WO-2012034232-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2012-03-22 | — | — | WO | claimed |
| US-20130267571-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| US-6991834-B1 | Materials for inducing alignment of liquid crystals and liquid crystal optical elements | ELSICON, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-6491988-B1 | POLYAMIC ACID, POLYAMIDE ESTER AND POLYIMIDES; ANISOTROPICALLY ABSORBING; EXPOSING LAYER TO POLARIZED LIGHT; CROSSLINKING DIAMINES HAVING SIDE CHAINS OF C3-C22 LINEAR AND BRANCHED AND PARTIALLY FLUORINATED HYDROCARBONSCHAINS | ELSICON, INC. | 2002-12-10 | — | — | US | disclosed |
| US-6313348-B1 | LIQUID CRYSTAL | GIBBONS WAYNE M (US) | 2001-11-06 | — | — | US | disclosed |
| US-6103322-A | POLYAMIC ACID | ELSICON INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0688325-A1 | PHOSPHONIC ACID DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-12-27 | — | — | EP | disclosed |
| WO-1994020508-A1 | PHOSPHONIC ACID DERIVATIVES | EISAI CO., LTD. (JP) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267571-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | PMP22, PTGES, GGPS1 | KMT2A 3842/4885MEN1 2728/4885CYP3A4 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.